State of New Jersey Common Pension Fund D maintained its stake in Nektar Therapeutics (NASDAQ:NKTR) during the second quarter, Holdings Channel reports. The firm owned 105,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. State of New Jersey Common Pension Fund D’s holdings in Nektar Therapeutics were worth $2,053,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in NKTR. Flinton Capital Management LLC increased its stake in Nektar Therapeutics by 11.1% in the first quarter. Flinton Capital Management LLC now owns 4,480 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 448 shares during the period. First Trust Advisors LP increased its stake in Nektar Therapeutics by 8.0% in the first quarter. First Trust Advisors LP now owns 2,249,950 shares of the biopharmaceutical company’s stock valued at $52,806,000 after buying an additional 166,521 shares during the period. Great West Life Assurance Co. Can increased its stake in Nektar Therapeutics by 7.0% in the first quarter. Great West Life Assurance Co. Can now owns 213,944 shares of the biopharmaceutical company’s stock valued at $5,019,000 after buying an additional 13,956 shares during the period. Tocqueville Asset Management L.P. increased its stake in Nektar Therapeutics by 16.9% in the first quarter. Tocqueville Asset Management L.P. now owns 234,402 shares of the biopharmaceutical company’s stock valued at $5,501,000 after buying an additional 33,850 shares during the period. Finally, Wells Fargo & Company MN increased its stake in Nektar Therapeutics by 7.4% in the first quarter. Wells Fargo & Company MN now owns 207,320 shares of the biopharmaceutical company’s stock valued at $4,866,000 after buying an additional 14,202 shares during the period. 93.02% of the stock is currently owned by institutional investors and hedge funds.

Shares of Nektar Therapeutics (NKTR) opened at 18.42 on Friday. The stock has a 50 day moving average of $20.53 and a 200-day moving average of $18.52. Nektar Therapeutics has a one year low of $11.41 and a one year high of $24.88. The stock’s market capitalization is $2.88 billion.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.04. The company had revenue of $34.60 million for the quarter, compared to the consensus estimate of $33.64 million. Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. The company’s revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.36) earnings per share. Equities analysts forecast that Nektar Therapeutics will post ($0.94) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Nektar Therapeutics (NKTR) Position Held by State of New Jersey Common Pension Fund D” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/08/18/nektar-therapeutics-nktr-position-held-by-state-of-new-jersey-common-pension-fund-d.html.

Several equities research analysts have commented on the stock. Jefferies Group LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Nektar Therapeutics in a report on Friday, July 21st. Zacks Investment Research raised shares of Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a report on Tuesday, August 1st. William Blair reaffirmed an “outperform” rating on shares of Nektar Therapeutics in a report on Tuesday, July 18th. HC Wainwright assumed coverage on shares of Nektar Therapeutics in a report on Monday, August 7th. They set a “buy” rating and a $31.00 price objective on the stock. Finally, BidaskClub downgraded shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Nektar Therapeutics has an average rating of “Buy” and an average price target of $26.10.

In related news, Director Lutz Lingnau sold 30,000 shares of the business’s stock in a transaction that occurred on Friday, July 14th. The stock was sold at an average price of $20.76, for a total transaction of $622,800.00. Following the completion of the transaction, the director now directly owns 53,450 shares in the company, valued at approximately $1,109,622. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Roy A. Whitfield acquired 35,000 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The shares were bought at an average price of $17.95 per share, with a total value of $628,250.00. Following the completion of the purchase, the director now owns 133,000 shares in the company, valued at approximately $2,387,350. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 138,389 shares of company stock valued at $2,908,403. 6.10% of the stock is currently owned by corporate insiders.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.